Autolus Therapeutics (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today reported its financial results for the fourth quarter and full year ended December 31, 2025.
Super League (NASDAQ:SLE), a creator and publisher of content experiences and media solutions across the world’s largest immersive platforms, today reported record-breaking financial results for the fourth quarter and full year ended December 31, 2025.
51Talk Online Education Group (NYSE:COE), a leading global online English education platform, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2025.
LM Funding America (NASDAQ:LMFA), a cryptocurrency mining and specialty finance company, today announced its financial results for the fourth quarter and full year ended December 31, 2025.
BioXcel Therapeutics (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today reported its financial results for the fourth quarter and full year ended December 31, 2025.
Instil Bio (NASDAQ:TIL), a clinical-stage biopharmaceutical company, today reported its financial results for the fourth quarter and full year ended December 31, 2025, while outlining a transformative shift in its corporate strategy.
AstraZeneca (NASDAQ:AZN) today announced positive high-level results from the OBERON and TITANIA Phase III trials, marking a historic milestone in the treatment of chronic obstructive pulmonary disease (COPD).
Legence (NASDAQ:LGN), a preeminent integrated provider of energy efficiency and sustainability solutions for the built environment, today reported record-breaking financial results for the fourth quarter and full year ended December 31, 2025.
SBC Medical Group Holdings (NASDAQ:SBC), a leading Management Services Organization (MSO) for a diverse range of medical franchises, today announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025.
Novo Nordisk (NYSE:NVO) today announced that the U.S. Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae), the first and only once-weekly, long-acting basal insulin for adults living with type 2 diabetes.
Gravity (NASDAQ:GRVY), a developer and publisher of online and mobile games, today announced its consolidated financial results for the fiscal year ended December 31, 2025.
Kopin (NASDAQ:KOPN), a developer of application-specific optical systems and high-performance microdisplays, today announced preliminary unaudited financial results for the fourth quarter ended December 27, 2025.
